M·CAM, Inc. releases Patently Obvious™ on the Intellectual Property behind Sanofi-Aventis’ proposed acquisition of Genzyme

Date:  Wed, 2010-09-08

M·CAM, Inc. releases Patently Obvious™ on the Intellectual Property behind Sanofi–Aventis’ proposed acquisition of Genzyme

CHARLOTTESVILLE, VA – September 8, 2010 –– M·CAM, Inc. released its Patently Obvious™ report today on the patent holdings of the Genzyme Corporation (NASDAQ:GENZ) On August 30th French drug maker Sanofi–Aventis SA (NYSE:SNY) went public with their offer to acquire Genzyme (NasdaqGS:GENZ) a Cambridge, Massachusetts based biotech company. The offer, at $69 dollars a share for a $18.5 billion total price, was rejected by Genzyme.

Sanofi–Aventis will have to fully consider the potential liabilities associated with owning Genzyme’s intellectual property before increasing their bid. Genzyme has faced a slew of troubles recently and the cracks run deeper than the surface.

M·CAM’s Patently Obvious™ is a weekly report providing visibility into potentially unconsidered alternatives, including art in the public domain, to patent holdings across a variety of technology areas.

M·CAM, Inc. is a global, full–service intellectual property and rights (IP&R) and intangible asset financial services firm. We provide the technical and financial systems that allow public and private markets to use IP&R and IA for regulated transactions in banking, securities, insurance, and public innovation investment and technology procurement. From our pioneering work in creating the world’s first standards–based innovation collateralization financial products for banking and securities to our work in grassroots innovator enablement and patent quality assurance programs, M·CAM provides the mechanism to balance the interests of public and commercial sectors to support and build thriving economies.

The M·CAM Patently Obvious™ report on Genzyme’s patents can be found HERE

Genzyme has over 450 active U.S. patents – all of which have been analyzed by M·CAM and are available in a limited edition M·CAM Triage™. If you wish to purchase the whole portfolio analysis, please contact info@m-cam.com.